NYSE:RCUSBiotechs
Arcus Biosciences (RCUS): Evaluating Valuation After $250 Million Equity Offering and New Underwriter Support
Arcus Biosciences (RCUS) just wrapped up a major follow-on equity offering, bringing in $250 million with a fresh lineup of co-lead underwriters. Moves like this matter for investors, since capital raises can shift both sentiment and future prospects.
See our latest analysis for Arcus Biosciences.
The $250 million capital raise follows strong momentum for Arcus Biosciences, whose share price has increased by nearly 39% over the last month and more than doubled in the past 90 days. While the...